Posted by Michael Wonder on 24 Mar 2022
U.S. FDA approves streamlined process for initiating HIV therapy with Cabenuva (cabotegravir and rilpivirine), the first and only complete long-acting injectable HIV treatment
24 March 2022 - Adults living with HIV now have an option to start injectable regimen without the need for an oral lead-in period first.
Janssen today announced the U.S. FDA has approved a label update for Cabenuva (cabotegravir and rilpivirine), giving health care professionals and people living with human immunodeficiency virus in the U.S. the option to start this once monthly or every two month injectable treatment without the need for the oral lead-in phase (daily cabotegravir and rilpivirine tablets, taken for one month prior to initiation of cabotegravir and rilpivirine injections).
